John Erickson Jr. RNA Disease Diagnostics (RNADD) appointed John Erickson, Jr. to the newly created position of president to lead day-to-day operations. He will report directly to company co-founder and executive...
Cantor Fitzgerald launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with an “overweight” rating and 12-month price target of $10. The stock closed at $2.66 on May 26. “We believe that the risk/reward profile is...
William Blair initiated coverage of Vaccitech plc (NASDAQ:VACC) with an “outperform” rating. The stock was quoted at $14.35 in afternoon trading on May 25. Vaccitech is a clinical-stage biotechnology company that...
SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...
Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...
iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...
RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular...
William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...
Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...
Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...
Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...
Maxim Group downgraded Co-Diagnostics (NASDAQ:CODX) to “hold” from “buy” and removed its priced target, citing COVID-19 testing and revenue growth, which appear “to have peaked.” The stock closed at $9.70 on March 26...
Leede Jones Gable initiated coverage of Cardiol Therapeutics (TSX:CRDL) with a “speculative buy” rating and price target of $12.50 (Canadian). The stock closed at $4.51 on March 24. Analyst Doug Loe, Ph.D., writes that...
Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...
BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...
Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...
William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...
Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...
Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...
H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...
Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...
Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...